Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer

Biomedical Imaging and Intervention Journal

Volumn 6, Issue 3, 2010, Pages

  Chitapanarux, I ^a   Tharavichitkul, E ^a   Lorvidhaya, V ^a   Sittitrai, P ^a   Pattarasakulchai, T ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Cisplatin; Concurrent chemoradiotherapy; Head and neck cancer; Ifosfamide; Induction chemotherapy; Paclitaxel

Indexed keywords

CISPLATIN; IFOSFAMIDE; MESNA; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DERMATITIS; DISEASE COURSE; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MAXILLA SINUS CANCER; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NOSE CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PHARYNGITIS; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LOCALIZATION; VOMITING;

EID: 77957363380     PISSN: None     EISSN: 18235530     Source Type: Journal    
DOI: 10.2349/biij.6.3.e23     Document Type: Article

References (12)

1. Wolf GT. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685-90.
2. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86(4):265-72.
3. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890-9.
4. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer. 2000;83(12):1594-8.
5. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949-55.
6. Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin fluorouracil with or without docetaxel for organ preservation in hypopharynx and larynx cancer. Proc Am Soc Clin Oncol. 2006;24:abstract 5506.
7. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23(34):8636-45.
8. Remenar E, Van Herpen C, Germa Lluch J, et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck: final analysis of EORTC 24971. Proc Am Soc Clin Oncol. 2006;24:abstract 5516.
9. Posner MR, Haddad RI, Wirth L, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004;31(6):778-85.
10. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16(4):1325-30.
11. Shin DM, Glisson BS, Khuri FR, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002;95(2):322-30.
12. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003;21(2):320-6.